GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia
June 10, 2024 – Other, Pharmaceutical – GSK, NHS Scotland, anaemia, myelofibrosis
- Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
- Momelotinib is the first JAK-inhibitor treatment to be made available on the NHS in Scotland specifically indicated for both newly diagnosed and previously ruxolitinib-treated adult myelofibrosis patients with moderate to severe anaemia.
10 June 2024 — London, UK — GSK today announced that the Scottish Medicines Consortium (SMC) has accepted Omjjara▼ (momelotinib) for use within NHS Scotland as an option for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, and who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib, if the company provides momelotinib according to the NHS Scotland Patient Access Scheme (PAS) arrangement. This decision makes momelotinib the first JAK inhibitor treatment to be made available on the NHS in Scotland for both newly diagnosed and previously ruxolitinib-treated adult myelofibrosis patients with moderate to severe anaemia.
Myelofibrosis is a rare type of blood marrow cancer that disrupts the body’s normal production of blood cells. It is estimated that there are approximately 175 people living with myelofibrosis in Scotland. Myelofibrosis can lead to splenomegaly (enlargement of the spleen), constitutional symptoms, such as fatigue, night sweats, bone pain, as well as low blood counts, including anaemia (deficiency of red blood cells) and thrombocytopenia (deficiency of platelets). Nearly all people living with myelofibrosis are estimated to develop anaemia over the course of the disease, and may require additional supportive care, including red blood cell (RBC) transfusions.
Antoine Herbaux, vice president UK Oncology, GSK, said: “We are pleased with today’s news as it provides another treatment option that may address unmet needs for eligible patients. Momelotinib is the first JAK inhibitor specifically indicated for the treatment of disease-related splenomegaly or symptoms in both newly diagnosed and previously ruxolitinib-treated adult myelofibrosis patients with moderate to severe anaemia to be made available on the NHS in Scotland.”
About GSK
GSK is committed to helping improve patient survival through transformational medicines, with a current focus on breakthroughs in immuno-oncology and tumour-cell targeting therapies, and development in haematologic malignancies, gynaecologic cancers and other solid tumours. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
